<DOC>
	<DOCNO>NCT00669890</DOCNO>
	<brief_summary>The addition gemtuzumab ozogamicin ( GO ) combination Busulfan/Cyclophosphamide follow AlloSCT patient high risk CD33+ AML/JMML/MDS safe well tolerate . This study attempt determine maximum tolerate dose immune therapy ( gemtuzumab ) give combination myeloablative ( high dose ) drug use study allogeneic stem cell transplant . ( Part A )</brief_summary>
	<brief_title>Allogenic Stem Cell Transplantation Patients With High Risk CD33+ AML/MDS/JMML</brief_title>
	<detailed_description>Gemtuzumab Ozogamicin ( CMA-676 ) chemotherapeutic agent consist recombinant humanize anti-CD33 antibody conjugate calicheamicin , highly potent cytotoxic antitumor antibiotic . The antibody portion Gemtuzumab bind specifically CD33 antigen , sialic acid-dependent adhesion protein express surface leukemia blast , normal leukemic myeloid colony-forming cell , include leukemic clonogenic precursor , exclude pluripotent hematopoietic stem cell nonhematopoietic cell . This result formation complex internalize , upon calicheamicin derivative release lysosome myeloid cell . The free calicheamicin derivative bind DNA , result DNA double strand break consequential cell death .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Eligibility Disease Status AML Induction Failure AML 1st , 2nd , 3rd Relapse ( &gt; 10 % bone marrow blast ) AML great equal 3rd CR MDS &gt; 6 % bone marrow blast diagnosis Secondary MDS less equal 5 % bone marrow myeloblast diagnosis JMML &gt; 6 % bone marrow myeloblasts diagnosis Disease Immunophenotype Patients ( AML ) receive gemtuzumab ozogamicin must express minimum &gt; 10 % =10 % CD33 positivity . Patients &lt; 10 % CD33 positivity receive gemtuzumab ozogamicin . Organ Function Patients must adequate organ function define : Adequate renal function define : Serum creatinine &lt; 1.5 x normal , Creatinine clearance radioisotope GFR 40 ml/min/m2 &gt; 60 ml/min/1.73 m2 equivalent GFR determine institutional normal range Adequate liver function define : Total bilirubin 1.5 x normal , SGOT ( AST ) SGPT ( ALT ) &lt; 2.0 x normal =2.0 x normal Adequate cardiac function define : Shortening fraction &gt; 27 % echocardiogram , Ejection fraction &gt; 47 % radionuclide angiogram echocardiogram Adequate pulmonary function define : DLCO &gt; 55 % =55 % PFT For child uncooperative , evidence dyspnea rest , exercise intolerance , pulse oximetry &gt; 94 % room air Patients active CNS AML/JMML/MDS disease time condition therapy Female patient pregnant ( positive HCG ) Karnofsky &lt; 50 % Lansky &lt; 50 % 10 year less Age &gt; 65 year Has receive gemtuzumab previous 30 day recover prior gemtuzumab therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>AML</keyword>
	<keyword>JMML</keyword>
	<keyword>MDS</keyword>
	<keyword>Allogenic Atem Cell Transplant</keyword>
	<keyword>Gemtuzumab Ozogamicin</keyword>
</DOC>